Figure 2a–c demonstrates that, in comparison to the Veh-treated stroke control group, systematic administration of SPAK inhibitor ZT-1a or NKCC1 inhibitor BMT significantly decreased total infarct volume (~ 30% or 27%, respectively, p < 0.05), and cortical infarct volume by ~ 42% or 40%, respectively (p < 0.05). The gene discussed is SLC12A2; the disease is stroke disorder.